Prostatype Genomics AB's quarterly market cap
declined
from Jun. 2023 (kr44.68 Mil) to Dec. 2023 (kr17.59 Mil) but then
increased
from Dec. 2023 (kr17.59 Mil) to Jun. 2024 (kr26.75 Mil).
Prostatype Genomics AB's annual market cap
declined
from Dec. 2021 (kr134.89 Mil) to Dec. 2022 (kr48.46 Mil) and
declined
from Dec. 2022 (kr48.46 Mil) to Dec. 2023 (kr17.59 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Prostatype Genomics AB's Enterprise Value for Today is kr74.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Prostatype Genomics AB's Market Cap
For the Diagnostics & Research subindustry, Prostatype Genomics AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prostatype Genomics AB's Market Cap Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Prostatype Genomics AB's Market Cap falls into.
Prostatype Genomics AB Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Prostatype Genomics AB's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prostatype Genomics AB (OSTO:PROGEN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Prostatype Genomics AB Market Cap Related Terms
Thank you for viewing the detailed overview of Prostatype Genomics AB's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSTO:PROGEN has been successfully added to your 